Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 495 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Overactive Bladder in Parkinson's Disease
Interventions
solifenacin succinate (VESIcare), placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia
Conditions
Parkinson Disease
Interventions
modafinil 50mg, Placebo oral capsule
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Parkinson Disease
Interventions
BIA 28-6156
Drug
Lead sponsor
Bial R&D Investments, S.A.
Industry
Eligibility
Not listed
U.S. locations
16
States / cities
Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 13 more
Conditions
Parkinson Disease
Interventions
DBS of the STN, DBS of the GPI
Procedure
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Pembrolizumab, Placebo for pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Placebo for olaparib, Bevacizumab, Docetaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
43
States / cities
Birmingham, Alabama • Tucson, Arizona • Burbank, California + 37 more
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
62
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Capecitabine, 5-fluorouracil, Docetaxel, Oxaliplatin, Leucovorin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more
Conditions
Parkinson's Disease
Interventions
deep brain stimulation
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
2
States / cities
Atlanta, Georgia • Cleveland, Ohio
Conditions
Esophageal Neoplasms
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more
Conditions
Parkinson's Disease
Interventions
Implantation of the Peripheral Nerve Graft
Procedure
Lead sponsor
Craig van Horne, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Lexington, Kentucky
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
[123I]B-CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin
Biological · Procedure · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Motor Training in PD

NCT02457832
Conditions
Parkinson Disease
Interventions
Adapted Tango Dancing, Behavioral Control (BC) Condition
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
Fresno, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Conditions
Parkinsonian Syndrome, Parkinson
Interventions
A series of questionnaires
Behavioral
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Parkinson Disease
Interventions
Phoressor II (IOMED)
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Results available

Telemedicine Intervention to Improve Physical Function

NCT01639469
Conditions
Parkinson's Disease
Interventions
Structured exercise, Lifestyle exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Parkinson Disease
Interventions
Digital music therapeutic, Active-Control
Device · Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
40 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 70 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Vibostolimab, Boserolimab, MK-4830, MK-0482, Ifinatamab Deruxtecan (I-DXd), HER3-DXd
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
Conditions
Cervical Cancer
Interventions
Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
30
States / cities
Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 25 more
Conditions
Parkinson's Disease (PD), Healthy Control Subjects
Interventions
[18F]AV-133
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Melanoma
Interventions
Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab, Lenvatinib, Favezelimab/Pembrolizumab, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 11 more